Straits Times Index
3,311.51 -1.97 (-0.06%) Nikkei
39,069.68 +282.30 (+0.73%) Hang Seng
19,650.20 +96.59 (+0.49%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,374.00 -647.12 (-0.97%) CMC Crypto 200
1,367.72 +13.30 (+0.98%)
Nuvectis Pharma, Inc. (NVCT)
After hours:
| Previous close | 6.53 |
| Open | 6.55 |
| Bid | 6.02 x 100 |
| Ask | 6.28 x 100 |
| Day's range | 6.07 - 6.60 |
| 52-week range | 5.92 - 18.65 |
| Volume | |
| Avg. volume | 104,146 |
| Market cap | 112.89M |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.00 |
GlobeNewswireNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. W
- GuruFocus.com
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
Performance Analysis and Future Outlook Amidst Clinical Progress
- GlobeNewswire
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell linesSeveral clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused
